U.S. Markets closed

I Ran A Stock Scan For Earnings Growth And Thermo Fisher Scientific (NYSE:TMO) Passed With Ease

Simply Wall St

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling short, can easily find investors. And in their study titled Who Falls Prey to the Wolf of Wall Street?' Leuz et. al. found that it is 'quite common' for investors to lose money by buying into 'pump and dump' schemes.

So if you're like me, you might be more interested in profitable, growing companies, like Thermo Fisher Scientific (NYSE:TMO). While that doesn't make the shares worth buying at any price, you can't deny that successful capitalism requires profit, eventually. Loss-making companies are always racing against time to reach financial sustainability, but time is often a friend of the profitable company, especially if it is growing.

See our latest analysis for Thermo Fisher Scientific

How Quickly Is Thermo Fisher Scientific Increasing Earnings Per Share?

As one of my mentors once told me, share price follows earnings per share (EPS). Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. As a tree reaches steadily for the sky, Thermo Fisher Scientific's EPS has grown 21% each year, compound, over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be smiling.

I like to take a look at earnings before interest and (EBIT) tax margins, as well as revenue growth, to get another take on the quality of the company's growth. Thermo Fisher Scientific maintained stable EBIT margins over the last year, all while growing revenue 5.6% to US$25b. That's a real positive.

The chart below shows how the company's bottom and top lines have progressed over time. To see the actual numbers, click on the chart.

NYSE:TMO Income Statement, December 21st 2019

Fortunately, we've got access to analyst forecasts of Thermo Fisher Scientific's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.

Are Thermo Fisher Scientific Insiders Aligned With All Shareholders?

We would not expect to see insiders owning a large percentage of a US$131b company like Thermo Fisher Scientific. But we do take comfort from the fact that they are investors in the company. Notably, they have an enormous stake in the company, worth US$259m. This suggests to me that leadership will be very mindful of shareholders' interests when making decisions!

Does Thermo Fisher Scientific Deserve A Spot On Your Watchlist?

You can't deny that Thermo Fisher Scientific has grown its earnings per share at a very impressive rate. That's attractive. I think that EPS growth is something to boast of, and it doesn't surprise me that insiders are holding on to a considerable chunk of shares. So this is very likely the kind of business that I like to spend time researching, with a view to discerning its true value. If you think Thermo Fisher Scientific might suit your style as an investor, you could go straight to its annual report, or you could first check our discounted cash flow (DCF) valuation for the company.

Of course, you can do well (sometimes) buying stocks that are not growing earnings and do not have insiders buying shares. But as a growth investor I always like to check out companies that do have those features. You can access a free list of them here.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.